Drug discovery

North America Cell-based Assays Market Report 2022: Featuring Becton, Dickinson, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche & More - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023

The "North America Cell-based Assays Market Size, Share & Industry Trends Analysis Report by Application (Drug Discovery, Basic Research and Others), End-user, Products & Services, Country and Growth Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Cell-based Assays Market Size, Share & Industry Trends Analysis Report by Application (Drug Discovery, Basic Research and Others), End-user, Products & Services, Country and Growth Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • These assays include cell viability assays, cell proliferation assays, and GPCR assays.
  • These high-throughput assays speed up the process of drug discovery by giving the most promising candidate in the biological context that matters the most.
  • The US market dominated the North America Cell-based Assays Market by Country in 2021; thereby, achieving a market value of $7.2 billion by 2028.

Global Toxicity Testing Outsourcing Market Report to 2028: Increased Efficiency in Drug Discovery and Personalized Therapy Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

The "Global Toxicity Testing Outsourcing Market Size, Share & Industry Trends Analysis Report by End-use, Method, GLP, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Toxicity Testing Outsourcing Market Size, Share & Industry Trends Analysis Report by End-use, Method, GLP, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Toxicity Testing Outsourcing Market size is expected to reach $4.9 billion by 2028, rising at a market growth of 8.4% CAGR during the forecast period.
  • The pharmaceutical business, biotechnology firms, contract research groups, or environmental scientists may all carry out toxicology testing.
  • Therefore, COVID-19 propelled the trend of outsourcing and as such had a positive impact on the toxicity testing outsourcing market.

Outlook on the RNA Analysis Global Market to 2028 - Featuring Illumina, Bio-Rad Laboratories, Eurofins Scientific and Merck Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

The Global RNA Analysis Market size is expected to reach $28 billion by 2028, rising at a market growth of 15.6% CAGR during the forecast period.

Key Points: 
  • The Global RNA Analysis Market size is expected to reach $28 billion by 2028, rising at a market growth of 15.6% CAGR during the forecast period.
  • The method used to produce RNA in a lab setting from a DNA template is known as in vitro transcription.
  • For use in procedures like in vitro translation, the investigation of RNA viruses, and RNA: protein interaction investigations, RNA is produced from DNA templates using in vitro transcription devices.
  • For use in RNA analysis research, single-stranded RNA probes, microgram amounts of specified RNA transcripts, and antisense RNA are all prepared using riboprobe systems.

DNA Synthesis Global Market Report 2023: Rapid Technological Advancements in the Field of Synthetic Biology Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

The global DNA synthesis market size is expected to reach USD 12.76 billion by 2030.

Key Points: 
  • The global DNA synthesis market size is expected to reach USD 12.76 billion by 2030.
  • In addition, DNA synthesis has the capability to revolutionize biological research activities for widespread applications in disease monitoring, drug discovery, and pharmacogenomics.
  • Progress in enzyme engineering is boosting the development of different approaches for enzymatic DNA synthesis.
  • Moreover, key market players are working towards entering the Asia Pacific market with their modern nucleotide production expertise

Vial Announces New Central Nervous System Scientific Advisory Board Member, Dr. Jacqueline French of the Epilepsy Study Consortium and NYU Grossman School of Medicine.

Retrieved on: 
Friday, January 13, 2023

Dr. French is a professor of neurology at the NYU Grossman School of Medicine, co-director of epilepsy clinical trials for NYU Langone Health's Comprehensive Epilepsy Center, and president, director, and founder of The Epilepsy Study Consortium.

Key Points: 
  • Dr. French is a professor of neurology at the NYU Grossman School of Medicine, co-director of epilepsy clinical trials for NYU Langone Health's Comprehensive Epilepsy Center, and president, director, and founder of The Epilepsy Study Consortium.
  • After receiving her medical education at Brown University, she completed a residency in neurology at Mount Sinai Hospital in New York.
  • Thereafter, she pursued further training through a fellowship in EEG and epilepsy at Mount Sinai Hospital and Yale University.
  • We are pleased to welcome Dr. French as she is an esteemed leader in clinical neurology research," said Simon Burns, CEO and Co-founder of Vial.

Cambrian BioPharma Unveils New Pipeline Company - Isterian Biotech

Retrieved on: 
Thursday, January 12, 2023

NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Cambrian BioPharma, a multi-asset longevity biotech, today unveils its latest pipeline company, Isterian Biotech. This preclinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during aging resulting in fibrotic diseases.

Key Points: 
  • NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today unveils its latest pipeline company, Isterian Biotech .
  • "Using this state-of-the-art approach to drug discovery combined with an impressive team gives us great confidence in the future of this novel company."
  • In 2019, Aston University partnered with Cambrian to form Isterian Biotech with a mission to develop safe and effective TG2 inhibitors to treat Idiopathic pulmonary fibrosis (IPF), a devastating fibrotic disease of the lung.
  • "Isterian and its work to reduce fibrosis are a perfect fit alongside the other pipeline companies our team has announced in 2022."

NEC announces plans for transition to a Company with a Nominating Committee, etc. and implementation of organizational reforms

Retrieved on: 
Monday, January 30, 2023

This decision is subject to approval at the Ordinary General Meeting of Shareholders scheduled to be convened in June 2023.

Key Points: 
  • This decision is subject to approval at the Ordinary General Meeting of Shareholders scheduled to be convened in June 2023.
  • NEC will separate the oversight function from execution by management in order to strengthen the oversight function of the Board of Directors.
  • By delegating substantial authority to executive officers with respect to business execution, NEC will accelerate timely decision-making and implementation.
  • Plans are slated for NEC to make its transition to a Company with a Nominating Committee, etc.

Research commenced with Keio University to discover drugs using "Chemicals Informatics"

Retrieved on: 
Thursday, January 12, 2023

Small molecule drugs are mainstream drugs in the modern world, and in recent years, expectations for their use have increased, with the development of drugs such as molecular-targeted drugs that inhibit the action of proteins, which cause cancer(2).

Key Points: 
  • Small molecule drugs are mainstream drugs in the modern world, and in recent years, expectations for their use have increased, with the development of drugs such as molecular-targeted drugs that inhibit the action of proteins, which cause cancer(2).
  • MI is expected to solve these challenges by using information science techniques, such as AI, to improve the efficiency of compound and material development.
  • In the Research, Keio University Faculty of Pharmacy, Department of Pharmaceutical Sciences will use Hitachi High-Tech Solutions' CI to study the development of new drugs to act as selective inhibitors that will block enzymes that produce active sulfur molecules.
  • (2) Molecular-targeted drugs: A therapeutic agent designed to act only on specific molecules that cause disease.

EQS-News: VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG

Retrieved on: 
Thursday, February 2, 2023

The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients.

Key Points: 
  • The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients.
  • VPM oversaw the clinical trial and performed translational project management, whereas the Australian cooperation partner and contract research organization (CRO) Accelagen managed the trial, yielding positive results, with all endpoints met.
  • In this phase I, single-blind, partially randomized, placebo-controlled clinical trial, 40 healthy adult volunteers were administered single and multiple ascending intravenous doses of AntiBKV (ClinicalTrials.gov: NCT05358106).
  • The broad expertise and commitment of VPM made the trial run smoothly, within budget and on time.

Syntekabio Inc.: 2023 Trends in New Drug Development

Retrieved on: 
Thursday, February 2, 2023

The webinar features panelists from Columbia University, Janssen, Syntekabio (KOSDAQ:226330.KQ) and Auctus Capital

Key Points: 
  • The webinar features panelists from Columbia University, Janssen, Syntekabio (KOSDAQ:226330.KQ) and Auctus Capital
    Syntekabio (KOSDAQ:226330.KQ)(226330:KS), a global AI drug discovery and development company, will participate in a special webinar hosted by the New York Health Forum (NYHF) on the latest drug discovery and development trends.
  • What is at the core of transforming a once lengthy process full of complexity and uncertainties?
  • Advancements in new technologies, including artificial intelligence (AI), Covid-19 and drug pricing legislation have disrupted drug discovery and development in the global biopharma industry.
  • Syntekabio is leading this industry-wide transformation with its latest invention STB CLOUD, which can give clinical-stage pharmaceutical companies with limited drug discovery capability an ideal one-stop solution for fully automatic drug discovery.